Literature DB >> 3391521

Cholesterol nucleation from its carriers in human bile.

Y Peled1, Z Halpern, R Baruch, G Goldman, T Gilat.   

Abstract

This study was performed to determine whether biliary cholesterol nucleates primarily from vesicles or micelles. Twenty gallbladder biles and 12 hepatic biles from patients with gallstones as well as 16 model biles were examined. The nucleation times (days) of the biles as well as their isolated vesicular and micellar fractions were determined and their lipid composition was analyzed. In 41 of 46 comparisons, cholesterol nucleated faster from vesicles than micelles; in only one case was the opposite found. The mean (+/- S.D.) nucleation times of vesicles and micelles in gallbladder biles were 8.9 +/- 5.4 vs. 15.4 +/- 8.6, in hepatic biles 14.6 +/- 9.4 vs. 20.6 +/- 9.1, and in model biles 9.0 +/- 3.7 vs. 18.9 +/- 9.1 days, respectively. All these differences were significant (p less than 0.005). Gallbladder biles (n = 7) devoid of vesicles nucleated more slowly (9.0 +/- 9.5 days), as compared to gallbladder biles (n = 13) containing vesicles (3.8 +/- 2.2 days). The nucleation time of gallbladder and hepatic biles was significantly correlated with the nucleation time of the vesicles from these biles (r = 0.847, p less than 0.05). There was no correlation with the nucleation time of micelles from the same biles. The percentage of cholesterol carried by vesicles in bile was positively correlated to the molar percentage of biliary cholesterol and the cholesterol saturation index and negatively correlated to the molar percentage of bile salts. Our data suggest that phospholipid vesicles are the major vehicle for cholesterol precipitation in bile as well as an important determinant of the nucleation time of bile.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391521     DOI: 10.1002/hep.1840080435

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Cryoelectron microscopy of a nucleating model bile in vitreous ice: formation of primordial vesicles.

Authors:  D L Gantz; D Q Wang; M C Carey; D M Small
Journal:  Biophys J       Date:  1999-03       Impact factor: 4.033

2.  The effects of dietary phospholipids enriched with phosphatidylethanolamine on bile and red cell membrane lipids in humans.

Authors:  R Pakula; F M Konikoff; M Rubin; Y Ringel; Y Peled; A Tietz; T Gilat
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

3.  The effects of short term lipid infusion on plasma and hepatic bile lipids in humans.

Authors:  R Pakula; F M Konikoff; A M Moser; F Greif; A Tietz; T Gilat; M Rubin
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

4.  Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile.

Authors:  S Mizuno; S Tazuma; G Kajiyama
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

5.  Distribution of cholesterol among its carriers in the bile of male and female hamsters.

Authors:  T Mikami; B I Cohen; Y Mikami; N Ayyad; E H Mosbach
Journal:  Lipids       Date:  1994-08       Impact factor: 1.880

6.  Characterization of a small vesicular cholesterol carrier in human gallbladder bile.

Authors:  S A Ahrendt; M K Fox-Talbot; H S Kaufman; K D Lillemoe; P A Lipsett; H A Pitt
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

7.  Effect of diosgenin on biliary cholesterol transport in the rat.

Authors:  A Thewles; R A Parslow; R Coleman
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

8.  Effect of lipid infusion on bile composition and lithogenicity in patients without cholesterol gall stones.

Authors:  M Rubin; Z Halpern; G Charach; A Dvir; E Antebi; T Gilat; D Lichtenberg
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

9.  Reduced cholesterol metastability of hepatic bile and its further decline in gall bladder bile in patients with cholesterol gall stones.

Authors:  K Nakano; K Chijiiwa
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.